Medicines Discovery Catapult (MDC) of the UK and Crown Bioscience have formed a strategic global alliance to accelerate innovation in radiopharmaceuticals through an integrated translational biology platform. The collaboration aims to support companies across the drug development pipeline by combining MDC’s expertise in radiochemistry, imaging and tissue analysis with Crown Bioscience’s preclinical oncology capabilities.
